Tissue Banking for Oncology, Organ Transplant Tissue
This study is similar in design and objectives to that of the previous cholangiocarcinoma study. It looks at changes of healthy tissues to hepatic syndromes. This study captures patients with precursor diseases to cholangiocarcinoma such as PSC, Ulcerative Colitis, IBD, and Crohns. Tissue is saved from patients who are undergoing a biopsy, operation, or other procedure. No extra tissue is harvested; just a portion of the tissue obtained for standard of care will be saved.
- Patients are usually eligible for the protocol once they have attained their eighteenth birthday and are undergoing a procedure where tissue from their kidney, liver, heart, brain, lung, adrenal, muscle, skin, stomach, intestine, etc.
Guidelines for Ineligiblity:
- Patients are usually excluded for medical co-morbidities that would preclude the use of general anesthesia. Pregnant patients and those patients hoping to become pregnant will not be eligible for the study.
How long does it run?
10,000 patients over the next ten years
Location(s) of clinical trial
University of Utah Hospital
Salt Lake City, Utah, United States, 84105
Principal Investigator: Jason Schwartz, M.D
Status: Open Enrollment
Name, Phone, Email
Contact: Jason Schwartz, M.D, 801-585-2708
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician, we can help you find a University of Utah doctor or clinic location to meet your health care needs.
Although the studies described on this site may have potential benefits as described, the University of Utah or its physicians and affiliated hospitals cannot and do not guarantee that you will receive any benefits from participating in a study.